90 related articles for article (PubMed ID: 3441058)
1. [The comparison of histories of hypertension and renal function between group III and group IV (Keith-Wagener criteria) malignant essential hypertension].
Sugiyama K; Sesoko S; Akema N; Gotoh E; Kaneko Y
Nihon Jinzo Gakkai Shi; 1987 Oct; 29(10):1301-6. PubMed ID: 3441058
[No Abstract] [Full Text] [Related]
2. Urinary kallikrein excretion is low in malignant essential hypertension.
Hilme E; Herlitz H; Gyzander E; Hansson L
J Hypertens; 1992 Aug; 10(8):869-74. PubMed ID: 1325521
[TBL] [Abstract][Full Text] [Related]
3. [Hypotensive effect of nephrectomy in malignant renal hypertension and the function of the remaining kidney at late follow-up].
Rustamova MT; Iunusov RA
Ter Arkh; 1984; 56(9):37-40. PubMed ID: 6515545
[TBL] [Abstract][Full Text] [Related]
4. [Pathophysiology and prognosis in malignant hypertension: comparison by underlying diseases].
Kawazoe N
Fukuoka Igaku Zasshi; 1989 Oct; 80(10):467-76. PubMed ID: 2515135
[TBL] [Abstract][Full Text] [Related]
5. [Malignant hypertension: clinical picture, treatment and evolution of 26 patients].
Franco RJ; Matsubara LS; Bonilha JP; Mota AC; Soares VA; Habermann F; Almeida DB
Arq Bras Cardiol; 1978 Feb; 31(1):45-22. PubMed ID: 655891
[No Abstract] [Full Text] [Related]
6. Long-term renal survival in malignant hypertension.
González R; Morales E; Segura J; Ruilope LM; Praga M
Nephrol Dial Transplant; 2010 Oct; 25(10):3266-72. PubMed ID: 20299339
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognosis in malignant or accelerated hypertension.
Guerin C; Gonthier R; Berthoux FC
Nephrol Dial Transplant; 1988; 3(1):33-7. PubMed ID: 3132637
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of electrocardiographic left ventricular hypertrophy in malignant hypertension and its correlation with renal function.
Islim IF; Beevers M; Muthuswamy S; Bannergy A; Singh SP; Beevers DG
J Hypertens Suppl; 1993 Dec; 11(5):S106-7. PubMed ID: 8158297
[No Abstract] [Full Text] [Related]
9. The short-term course of renal function in malignant hypertensives with renal insufficiency.
Lawton WJ
Clin Nephrol; 1982 Jun; 17(6):277-83. PubMed ID: 7105502
[TBL] [Abstract][Full Text] [Related]
10. [Course of renal function in malignant hypertension. Effect of treatment. Study of 30 cases followed for 5 to 18 years].
Laville M; Arkouche W; Pozet N; Hadj-Aissa A; Labeeuw M; Zech P
Arch Mal Coeur Vaiss; 1986 Jun; 79(6):767-72. PubMed ID: 3099691
[TBL] [Abstract][Full Text] [Related]
11. Kidney histology and clinical correlates in malignant hypertension.
Kadiri S; Thomas JO
East Afr Med J; 1993 Feb; 70(2):112-6. PubMed ID: 8513738
[TBL] [Abstract][Full Text] [Related]
12. Malignant hypertension. A clinical follow-up study with special reference to renal and cardiovascular function and immunogenetic factors.
Gudbrandsson T
Acta Med Scand Suppl; 1981; 650():1-62. PubMed ID: 6948498
[No Abstract] [Full Text] [Related]
13. [Value of kidney function tests in chronic pyelonephritis and renal artery stenosis].
Spivak GL
Ter Arkh; 1972 Feb; 44(2):55-9. PubMed ID: 5039701
[No Abstract] [Full Text] [Related]
14. Short-term course of renal function in accelerated hypertension.
Kadiri S; Olutade BO
Afr J Med Med Sci; 1993 Mar; 22(1):25-9. PubMed ID: 7880319
[TBL] [Abstract][Full Text] [Related]
15. Does lead play a role in the development of renal insufficiency in some patients with essential hypertension?
Lin JL; Lim PS
J Hum Hypertens; 1994 Jul; 8(7):495-500. PubMed ID: 7932512
[TBL] [Abstract][Full Text] [Related]
16. Return of renal function after commencing maintenance hemodialysis.
Maxey RW; Rao TK; Manis T; Delano BG; Friedman EA
Proc Clin Dial Transplant Forum; 1975 Nov; 5():12-5. PubMed ID: 1232623
[No Abstract] [Full Text] [Related]
17. [Malignant arterial hypertension, symptomatic and prognostic aspects. Retrospective study of 140 cases].
Guelpa G; Lucsko M; Chaignon M; Guedon J
Schweiz Med Wochenschr; 1984 Dec; 114(50):1870-7. PubMed ID: 6515387
[TBL] [Abstract][Full Text] [Related]
18. [Serum creatinine and creatinine clearance to estimate renal function in essential hypertension].
Jabary NS; Martín D; Muñoz MF; Santos M; Herruzo J; Gordillo R; Bustamante J
Nefrologia; 2006; 26(1):64-73. PubMed ID: 16649427
[TBL] [Abstract][Full Text] [Related]
19. Renal revascularization as treatment for malignant hypertension.
Laroche GP; Lachance JG; Lebel M
Can J Surg; 1980 Jul; 23(4):329-42. PubMed ID: 7417891
[TBL] [Abstract][Full Text] [Related]
20. [Captopril in essential malignant arterial hypertension with renal insufficiency].
Martínez Fernández R; Fernández Rodríguez R; Lizasoaín Hernández M; Praga Terente M; Alcázar de la Ossa JM; Rodicio Díaz JL
Rev Clin Esp; 1988 Sep; 183(4):184-9. PubMed ID: 3072603
[No Abstract] [Full Text] [Related]
[Next] [New Search]
